Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

Completed · Phase 4

Conditions studied: Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder

In brief

This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces symptoms of social anxiety in this patient population.

Key facts

Study ID
NCT00177008
Run by
University of Medicine and Dentistry of New Jersey
People needed
18
Starts
2004-03-01
Expected to finish
2007-01-01
Last updated by the study team
2007-01-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.